Cargando…

Use of analgesics in France, following dextropropoxyphene withdrawal

BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Ganse, E., Belhassen, M., Ginoux, M., Chrétien, E., Cornu, C., Ecoffey, C., Aubrun, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880096/
https://www.ncbi.nlm.nih.gov/pubmed/29609613
http://dx.doi.org/10.1186/s12913-018-3058-1
_version_ 1783311115603673088
author Van Ganse, E.
Belhassen, M.
Ginoux, M.
Chrétien, E.
Cornu, C.
Ecoffey, C.
Aubrun, F.
author_facet Van Ganse, E.
Belhassen, M.
Ginoux, M.
Chrétien, E.
Cornu, C.
Ecoffey, C.
Aubrun, F.
author_sort Van Ganse, E.
collection PubMed
description BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators recommended that DXP/PC be replaced by other step 2 analgesics, i.e. tramadol, codeine, or opium-containing drugs, or by PC for a weak level of pain. To investigate prescribing behaviours after DXP/PC withdrawal, dispensations of analgesics before and after withdrawal were analysed. METHODS: Aggregated dispensation data of analgesics prescribed between January 2009 and December 2012 in the Rhône-Alpes region were obtained from the general health insurance claims data; changes in analgesic dispensation over time were analysed with the ATC/DDD methodology. Pre (Jan-June 2009) and post-withdrawal (Jan-June 2012) changes of DDDs where computed for each analgesic step. RESULTS: The dispensations of DXP/PC experienced a two-step decrease until 2011. Over the withdrawal period 2009-2012, there was a 14% decrease in the overall use of analgesic (from 109 to 94 DDDs), while the use of step 2 analgesics declined by 46% (− 22 DDDs, from 47 to 25 DDDs). This latter decline included a cessation of use of DXP/PC (29 DDDs in 2009) that were only in part (+ 7 DDDs, from 18 to 25 DDDs) compensated by increased use of codeine, tramadol and opium, in monotherapy or combined with PC. For step 1 analgesics, use increased with 9%, mostly PC (+ 8 DDDs, from 31 to 39 DDDs). Step 3 analgesics dispensations remained largely unchanged over this period (around 3 DDDs). CONCLUSIONS: In the Rhône-Alpes region, DXP/PC withdrawal was accompanied in part by an increased use of same level analgesics, and in part by an increased use of PC in monotherapy. The extent of DXP/PC use before withdrawal, and the increased use of PC after DXP withdrawal, underline the complexity of pain management.
format Online
Article
Text
id pubmed-5880096
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58800962018-04-04 Use of analgesics in France, following dextropropoxyphene withdrawal Van Ganse, E. Belhassen, M. Ginoux, M. Chrétien, E. Cornu, C. Ecoffey, C. Aubrun, F. BMC Health Serv Res Research Article BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators recommended that DXP/PC be replaced by other step 2 analgesics, i.e. tramadol, codeine, or opium-containing drugs, or by PC for a weak level of pain. To investigate prescribing behaviours after DXP/PC withdrawal, dispensations of analgesics before and after withdrawal were analysed. METHODS: Aggregated dispensation data of analgesics prescribed between January 2009 and December 2012 in the Rhône-Alpes region were obtained from the general health insurance claims data; changes in analgesic dispensation over time were analysed with the ATC/DDD methodology. Pre (Jan-June 2009) and post-withdrawal (Jan-June 2012) changes of DDDs where computed for each analgesic step. RESULTS: The dispensations of DXP/PC experienced a two-step decrease until 2011. Over the withdrawal period 2009-2012, there was a 14% decrease in the overall use of analgesic (from 109 to 94 DDDs), while the use of step 2 analgesics declined by 46% (− 22 DDDs, from 47 to 25 DDDs). This latter decline included a cessation of use of DXP/PC (29 DDDs in 2009) that were only in part (+ 7 DDDs, from 18 to 25 DDDs) compensated by increased use of codeine, tramadol and opium, in monotherapy or combined with PC. For step 1 analgesics, use increased with 9%, mostly PC (+ 8 DDDs, from 31 to 39 DDDs). Step 3 analgesics dispensations remained largely unchanged over this period (around 3 DDDs). CONCLUSIONS: In the Rhône-Alpes region, DXP/PC withdrawal was accompanied in part by an increased use of same level analgesics, and in part by an increased use of PC in monotherapy. The extent of DXP/PC use before withdrawal, and the increased use of PC after DXP withdrawal, underline the complexity of pain management. BioMed Central 2018-04-02 /pmc/articles/PMC5880096/ /pubmed/29609613 http://dx.doi.org/10.1186/s12913-018-3058-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Van Ganse, E.
Belhassen, M.
Ginoux, M.
Chrétien, E.
Cornu, C.
Ecoffey, C.
Aubrun, F.
Use of analgesics in France, following dextropropoxyphene withdrawal
title Use of analgesics in France, following dextropropoxyphene withdrawal
title_full Use of analgesics in France, following dextropropoxyphene withdrawal
title_fullStr Use of analgesics in France, following dextropropoxyphene withdrawal
title_full_unstemmed Use of analgesics in France, following dextropropoxyphene withdrawal
title_short Use of analgesics in France, following dextropropoxyphene withdrawal
title_sort use of analgesics in france, following dextropropoxyphene withdrawal
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880096/
https://www.ncbi.nlm.nih.gov/pubmed/29609613
http://dx.doi.org/10.1186/s12913-018-3058-1
work_keys_str_mv AT vangansee useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT belhassenm useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT ginouxm useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT chretiene useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT cornuc useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT ecoffeyc useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal
AT aubrunf useofanalgesicsinfrancefollowingdextropropoxyphenewithdrawal